BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 27879973)

  • 1. Application of the Immunoscore as prognostic tool for hepatocellular carcinoma.
    Petrizzo A; Buonaguro L
    J Immunother Cancer; 2016; 4():71. PubMed ID: 27879973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.
    Gabrielson A; Wu Y; Wang H; Jiang J; Kallakury B; Gatalica Z; Reddy S; Kleiner D; Fishbein T; Johnson L; Island E; Satoskar R; Banovac F; Jha R; Kachhela J; Feng P; Zhang T; Tesfaye A; Prins P; Loffredo C; Marshall J; Weiner L; Atkins M; He AR
    Cancer Immunol Res; 2016 May; 4(5):419-30. PubMed ID: 26968206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of tumor-infiltrating immunocytes for predicting prognosis of hepatitis B virus-related hepatocellular carcinoma.
    Chen QF; Li W; Wu PH; Shen LJ; Huang ZL
    World J Gastroenterol; 2019 Sep; 25(35):5266-5282. PubMed ID: 31558872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.
    Kirilovsky A; Marliot F; El Sissy C; Haicheur N; Galon J; Pagès F
    Int Immunol; 2016 Aug; 28(8):373-82. PubMed ID: 27121213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD1
    Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
    J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive value of centre tumour CD8⁺ T cells in patients with hepatocellular carcinoma: comparison with Immunoscore.
    Sun C; Xu J; Song J; Liu C; Wang J; Weng C; Sun H; Wei H; Xiao W; Sun R; Tian Z
    Oncotarget; 2015 Nov; 6(34):35602-15. PubMed ID: 26415232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Immunoscore is a Superior Prognostic Tool in Stages II and III Colorectal Cancer and is Significantly Correlated with Programmed Death-Ligand 1 (PD-L1) Expression on Tumor-Infiltrating Mononuclear Cells.
    Yomoda T; Sudo T; Kawahara A; Shigaki T; Shimomura S; Tajiri K; Nagasu S; Fujita F; Kinugasa T; Akagi Y
    Ann Surg Oncol; 2019 Feb; 26(2):415-424. PubMed ID: 30569297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III Gastric Cancer.
    Wen T; Wang Z; Li Y; Li Z; Che X; Fan Y; Wang S; Qu J; Yang X; Hou K; Zhou W; Xu L; Li C; Wang J; Liu J; Chen L; Zhang J; Qu X; Liu Y
    Cancer Immunol Res; 2017 Jul; 5(7):524-534. PubMed ID: 28619967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression on the Roles and Mechanisms of Tumor-Infiltrating T Lymphocytes in Patients With Hepatocellular Carcinoma.
    Zheng X; Jin W; Wang S; Ding H
    Front Immunol; 2021; 12():729705. PubMed ID: 34566989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Role of Immune Cells in Hepatitis B-associated Hepatocellular Carcinoma Following Surgical Resection Depends on Their Localization and Tumor Size.
    Wang Q; Luan W; Warren L; Fiel MI; Blank S; Kadri H; Mandeli J; Hiotis SP
    J Immunother; 2016 Jan; 39(1):36-44. PubMed ID: 26641260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer.
    Ko YS; Pyo JS
    Int J Biol Markers; 2019 Jun; 34(2):132-138. PubMed ID: 30852949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?
    Yang HY; Sun LJ; Mao YL
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):93-94. PubMed ID: 29576280
    [No Abstract]   [Full Text] [Related]  

  • 13. Margin-infiltrating CD20(+) B cells display an atypical memory phenotype and correlate with favorable prognosis in hepatocellular carcinoma.
    Shi JY; Gao Q; Wang ZC; Zhou J; Wang XY; Min ZH; Shi YH; Shi GM; Ding ZB; Ke AW; Dai Z; Qiu SJ; Song K; Fan J
    Clin Cancer Res; 2013 Nov; 19(21):5994-6005. PubMed ID: 24056784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma.
    He G; Zhang H; Zhou J; Wang B; Chen Y; Kong Y; Xie X; Wang X; Fei R; Wei L; Chen H; Zeng H
    J Exp Clin Cancer Res; 2015 Nov; 34():141. PubMed ID: 26581194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells.
    Lin SZ; Chen KJ; Xu ZY; Chen H; Zhou L; Xie HY; Zheng SS
    Cancer Prev Res (Phila); 2013 Jun; 6(6):594-602. PubMed ID: 23599540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
    Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
    Front Immunol; 2018; 9():2077. PubMed ID: 30254644
    [No Abstract]   [Full Text] [Related]  

  • 17. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8
    Li J; Lee Y; Li Y; Jiang Y; Lu H; Zang W; Zhao X; Liu L; Chen Y; Tan H; Yang Z; Zhang MQ; Mak TW; Ni L; Dong C
    Immunity; 2018 Apr; 48(4):773-786.e5. PubMed ID: 29625896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1
    Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Matsutani S; Hirakawa K; Ohira M
    Anticancer Res; 2017 Aug; 37(8):4165-4172. PubMed ID: 28739701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan.
    Minagawa M; Ikai I; Matsuyama Y; Yamaoka Y; Makuuchi M
    Ann Surg; 2007 Jun; 245(6):909-22. PubMed ID: 17522517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer.
    Donnem T; Hald SM; Paulsen EE; Richardsen E; Al-Saad S; Kilvaer TK; Brustugun OT; Helland A; Lund-Iversen M; Poehl M; Olsen KE; Ditzel HJ; Hansen O; Al-Shibli K; Kiselev Y; Sandanger TM; Andersen S; Pezzella F; Bremnes RM; Busund LT
    Clin Cancer Res; 2015 Jun; 21(11):2635-43. PubMed ID: 25680376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.